Today is effectively the final day of ASH but it was still full of information, and to be honest, I’m a bit brain-fried. However, the day was broken up with the opportunity to meet with several Pharma companies: Takeda (Velcade, Ninlaro), who discussed their new Patient Advocacy Liaisons (Oncology Nurses) who will offer presentations to […]
Jack Aiello
Diagnosed with myeloma in 1995, Jack is strong proponent of patients participating in clinical trials so that, in the future, myeloma and other cancers will be known as curable diseases. He is a proud facilitator of the San Francisco Bay Area Myeloma Support Group.
Follow Jack on Twitter
Day 2 ASH: Transplant is still a promising treatment, but MRD is King
Today began with watching ASH abstract presentations from yesterday. This is actually one of the benefits of attending the meeting virtually. Presentations are often scheduled at the same time and at the in-person meeting, you need to make a decision which to attend. But being virtual, I’m able to watch a replay of a session […]
Day 1 ASH: It’s All About Immunotherapy
Dec 5, 2020 Today I actually began watching ASH (American Society of Hematology) President Dr. Stephanie Lee interview Dr. Fauci. I appreciated that one of the questions she asked was “Should cancer patients with compromised immune systems get the vaccine?” He said that he understands that cancer patients may actually be getting immunosuppressants, and the […]
Symposium Day Blog: But there’s more…
The Friday before the official start of ASH is always considered Symposium day. However, even before Friday, there are typically more meetings of different groups. And even though this year’s 62nd American Society of Hematology (ASH) meeting is virtual, there’s no exception to pre-Symposium day meetings and I’ve attended three already. The first was a […]
All Virtual, All-Amazing
There is no other single conference where so much information is presented about myeloma. Information about so many topics is provided: how to treat MM patients in various stages; results of phase II & III trials which may indicate upcoming FDA approvals; pre-clinical research focusing on myeloma targets and cell understanding; and more. However, this year […]